

# Tzu-Fei Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8333729/publications.pdf>

Version: 2024-02-01

104  
papers

3,323  
citations

318942

23  
h-index

175968

55  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4040  
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
2	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1289-1303.	2.3	168
3	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
4	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. <i>Thrombosis and Haemostasis</i> , 2014, 111, 88-93.	1.8	120
5	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	2.0	112
6	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	1.9	107
7	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1079-1095.	2.3	100
8	Functional Analysis of Human Hematopoietic Stem Cell Gene Expression Using Zebrafish. <i>PLoS Biology</i> , 2005, 3, e254.	2.6	96
9	Statins Are Associated With Reduced Mortality in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4008-4014.	0.8	76
10	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. <i>Thrombosis Research</i> , 2015, 135, 616-620.	0.8	75
11	Anticoagulation of cancer patients with non-atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1247-1252.	1.9	60
12	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2022, 6, 1661-1670.	2.5	56
13	Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. <i>Thrombosis Research</i> , 2020, 185, 13-19.	0.8	52
14	The role of thrombolytic therapy in pulmonary embolism. <i>Blood</i> , 2015, 125, 2191-2199.	0.6	47
15	A cross-sectional analysis of cardiovascular disease in the hemophilia population. <i>Blood Advances</i> , 2018, 2, 1325-1333.	2.5	43
16	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. <i>Thrombosis Research</i> , 2014, 133, 25-29.	0.8	42
17	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1866-1874.	1.9	42
18	Managing thrombosis in cancer patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 429-438.	1.0	40

#	ARTICLE	IF	CITATIONS
19	Aflibercept in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7432.	0.6	39
20	Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. <i>Thrombosis Research</i> , 2016, 143, 86-90.	0.8	37
21	Anticoagulation practice patterns in COVID-19: A global survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 969-983.	1.0	35
22	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	3.1	31
23	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	1.9	26
24	What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 714-716.	0.9	25
25	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
26	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies: TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
27	Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. <i>Blood Advances</i> , 2021, 5, 5546-5553.	2.5	23
28	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	1.9	22
29	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4606.	1.7	22
30	Presence and degree of residual venous obstruction on serial duplex imaging is associated with increased risk of recurrence and progression of infrainguinal lower extremity deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 575-583.e1.	0.9	21
31	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2468-2479.	1.9	21
32	How I treat obese patients with oral anticoagulants. <i>Blood</i> , 2020, 135, 904-911.	0.6	17
33	Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12634.	1.0	16
34	Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. <i>Thrombosis Research</i> , 2021, 204, 114-122.	0.8	15
35	Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2018, 59, 2377-2382.	0.6	13
36	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 337-341.	0.6	12

#	ARTICLE	IF	CITATIONS
37	A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer – A real world experience. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 793-800.	0.5	12
38	Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. <i>Oncologist</i> , 2021, 26, e17-e23.	1.9	12
39	Predictive ability of the khorana score for venous thromboembolism (VTE) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18733-e18733.	0.8	12
40	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <i>Cancer</i> , 2021, 127, 938-945.	2.0	11
41	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 202, 151-154.	0.8	11
42	Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2018, 132, 1248-1248.	0.6	11
43	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 399-402.	1.2	10
44	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 2807-2812.	2.5	10
45	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 830-841.	1.8	10
46	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10
47	Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score. <i>Blood</i> , 2018, 132, 141-141.	0.6	10
48	Plasmacytoma-Like Post-Transplantation Lymphoproliferative Disease Occurring in a Cardiac Allograft: A Case Report and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2012, 30, e278-e282.	0.8	8
49	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12517.	1.0	8
50	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboembolism Network U.S. retrospective cohort study. <i>Thrombosis Research</i> , 2021, 202, 155-161.	0.8	8
51	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. <i>CJC Open</i> , 2022, 4, 315-323.	0.7	8
52	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022, 213, S66-S71.	0.8	7
53	Thrombosis and bleeding in hematological malignancy. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101353.	0.7	7
54	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1366-1370.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 209S-216S.	0.7	6
56	&lt;p&gt;Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 11743-11749.	0.9	5
57	A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 16-22.	0.5	5
58	Comparison of Direct Oral Anticoagulants Versus Low-Molecular-Weight-Heparins for the Treatment of Cancer Associated Thrombosis. <i>Blood</i> , 2016, 128, 5013-5013.	0.6	5
59	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 208, 58-65.	0.8	5
60	A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1&acron;month of anticoagulation after catheter removal. <i>Blood Coagulation and Fibrinolysis</i> , 2022, 33, 171-175.	0.5	5
61	The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data. <i>Stroke Research and Treatment</i> , 2017, 2017, 1-4.	0.5	4
62	Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 70.	0.4	4
63	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. <i>Blood</i> , 2020, 136, 669-673.	0.6	4
64	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2014, 124, 2836-2836.	0.6	4
65	Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6585-6585.	0.8	4
66	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 208, 79-82.	0.8	4
67	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1169-1176.	1.8	4
68	How to treat incidental pulmonary embolism in cancer patients? Recent advances. <i>Kardiologia Polska</i> , 2021, 79, 1305-1310.	0.3	4
69	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e2219128.	2.8	4
70	Molecular structural analysis of a novel and de&acron;novo mutation in the <i><sc>SERPINC1</sc></i> gene associated with type 1 antithrombin deficiency. <i>British Journal of Haematology</i> , 2017, 177, 654-656.	1.2	3
71	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. <i>Journal of Women's Health</i> , 2021, 30, 829-836.	1.5	3
72	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019, 134, 325-325.	0.6	3

#	ARTICLE	IF	CITATIONS
73	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. Blood, 2013, 122, 5492-5492.	0.6	3
74	Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2020, 9, IJH28.	0.7	3
75	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thrombosis Research, 2022, 211, 85-87.	0.8	3
76	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-ASCC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	1.9	3
77	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2015, 126, 761-761.	0.6	2
78	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. Cancer Medicine, 2021, 10, 7601-7609.	1.3	1
79	Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase.. Journal of Clinical Oncology, 2019, 37, e18520-e18520.	0.8	1
80	Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia. Annals of Hematology, 2021, , 1.	0.8	1
81	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. Blood, 2019, 134, 1130-1130.	0.6	1
82	Safety and Efficacy of Apixaban Thromboprophylaxis in Ambulatory Cancer Patients By Renal Function: A Subgroup Analysis of the Avert Trial. Blood, 2021, 138, 3229-3229.	0.6	1
83	Phase I Study of Brentuximab Vedotin for the Prevention of Acute GvHD after Unrelated Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S413.	2.0	0
84	Von Willebrand's Disease and Pregnancy: A Single Center Experience [10K]. Obstetrics and Gynecology, 2017, 129, 114S-114S.	1.2	0
85	50. Different cytogenetic culture conditions yield surprising results. Cancer Genetics, 2018, 224-225, 69.	0.2	0
86	Thromboprophylaxis in patients with multiple myeloma. British Journal of Haematology, 2020, 190, 493-494.	1.2	0
87	New onset of acute heavy menstrual bleeding in a 34-year-old woman. Cmaj, 2021, 193, E1173-E1176.	0.9	0
88	Survival in patients with cancer-associated thrombosis in relation to anticoagulants: Re-evaluation of warfarin?. Journal of Thrombosis and Haemostasis, 2021, 19, 2677-2679.	1.9	0
89	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis.. Blood, 2012, 120, 2248-2248.	0.6	0
90	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients.. Blood, 2012, 120, 2268-2268.	0.6	0

#	ARTICLE	IF	CITATIONS
91	The Incidence, Characteristics, and Outcomes of Venous Thromboembolism in Patients with Follicular Lymphoma Compared to Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 5090-5090.	0.6	0
92	Von Willebrand Factor for Menorrhagia: A Survey and Literature Review. <i>Blood</i> , 2015, 126, 4694-4694.	0.6	0
93	A Retrospective Study of Clinical and Laboratory Characteristics in Patients Diagnosed with Platelet Storage Pool Deficiency. <i>Blood</i> , 2018, 132, 1148-1148.	0.6	0
94	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. <i>Blood</i> , 2018, 132, 2479-2479.	0.6	0
95	Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3148-3148.	0.6	0
96	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14170-e14170.	0.8	0
97	Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks. <i>Blood</i> , 2019, 134, 3681-3681.	0.6	0
98	Analysis of bleeding risk with concurrent treatment of VEGFR tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19305-e19305.	0.8	0
99	Maternal Outcomes in Women with Bleeding Disorders According to Mode of Delivery: A Single-Center Retrospective Cohort Study. <i>Blood</i> , 2021, 138, 494-494.	0.6	0
100	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 2139-2139.	0.6	0
101	Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism. <i>Blood</i> , 2021, 138, 4297-4297.	0.6	0
102	Bleeding Outcomes in Patients with Gastrointestinal Malignancies Treated with Distally Absorbed Versus Proximally Absorbed Direct Oral Anticoagulants. <i>Blood</i> , 2021, 138, 3027-3027.	0.6	0
103	Prospective Cohort of Catheter Related Thrombosis in Patients Treated with One Month of Anticoagulation after Catheter Removal. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
104	Source of upper gastrointestinal bleeding in cancer patients: A cross-sectional study. <i>Thrombosis Research</i> , 2022, 217, 9-11.	0.8	0